ACP 103,
ACP-103,
ACP103,
bis(1-(4-fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-(4-(2-methylpropoxy)benzyl)urea) (2R,3R)-2,3-dihydroxybutanedioate,
N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide,
Nuplazid,
Pimavanserin,
pimavanserin tartrate,
urea, n-((4-fluorophenyl)methyl)-n-(1-methyl-4-piperidinyl)-n'-((4-(2-methylpropoxy)phenyl)methyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1),
Pimavanserin tartrate,
706782-28-7,
Nuplazid,
UNII-NA83F1SJSR,
ACP 103,
ACP-103,
NA83F1SJSR,
Pimavanserin tartrate [USAN],
Pimavanserin Dihydroxysuccinate(2:1),
Bis(1-(4-Fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-(4-(2-methylpropoxy)benzyl)urea) (2R,3R)-2,3-dihydroxybutanedioate,
Pimavanserin tartrate (USAN),
Nuplazide (TN),
ACP-103 tartrate,
pimavanserin hemitartrate,
DTXSID50220958,
CHEBI:133014,
HY-14557A,
AKOS027327334,
CS-7954,
1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea (2R,3R)-2,3-dihydroxysuccinate,
AC-29901,
N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1),
N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide,
SC-90507,
Urea, N-((4-fluorophenyl)methyl)-N-(1-methyl-4-piperidinyl)-N'-((4-(2-methylpropoxy)phenyl)methyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1),
LS-193533,
D08969,
bis(4-{[(4-fluorophenyl)methyl]({[4-(2-methylpropoxy)phenyl]methyl}carbamoyl)amino}-1-methylpiperidin-1-ium) (2R,3R)-2,3-dihydroxybutanedioate,
bis{N-[(4-fluorophenyl)methyl]-N-(1-methylpiperidin-4-yl)-N'-{[4-(2-methylpropoxy)phenyl]methyl}urea} (2R,3R)-2,3-dihydroxybutanedioate,
Pimavanserin,
ACP103,
706782-28-7 (tartrate),
ACN-037476,
CID11672491,
Pimavanserin tartrate, 99% - 250MG 250mg,
C510793,
1-(4-Fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)urea ((2R,3R)-2,3-dihydroxysuccinate)(21),